TapewireFind a company

person · Reporting owner

PIMSTONE SIMON N.

Disclosed activity across 1 company

Tapewire entity
112810
SEC CIK
0001620084

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Xenon Pharmaceuticals Inc.XENE · Entity 2602DirectorJune 02, 2023June 02, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Xenon Pharmaceuticals Inc.

Report date June 02, 2023 · Filed June 02, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2033-06-01Direct18,475 Reported balance After 2023-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-02 · Grant · Acquired 18,475 · Balance 18,475

F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 5,037 $30.60 $154,132.20
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 7

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,735

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4865 to $30.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,990 $30.23 $60,157.70
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 6

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,772

F5 · price: Represents the closing price of the Company's common shares on March 4, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 20,576 $3.67 $75,513.92
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 5

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,762

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 10,288 $0.00 Strike: $3.67 $0.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · derivative · entry 20

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 10,288 shares

Expires 2022-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F12 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date.

F13 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 4,793 $30.56 $146,474.08
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 4

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,186

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.53 to $30.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 4,532 $30.66 $138,951.12
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,979

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.49 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 963 $31.42 $30,257.46
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,511

F2 · price: Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 10,288 $3.67 $37,756.96
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
November 15, 2021 Filed Nov 16, 2021 20:40 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 17,557 $31.33 $550,060.81
Disclosure

SEC source: 0001209191-21-064931 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,186

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
May 24, 2021 Filed May 26, 2021 16:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 22,633 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001209191-21-035911 · doc4.xml · derivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 22,633 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F3 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2011 Vesting Commencement Date.

F4 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.

Read SEC document
May 24, 2021 Filed May 26, 2021 16:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 5,076 $19.17 $97,306.92
Disclosure

SEC source: 0001209191-21-035911 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,743

F2 · price: Represents the closing price of the Company's common shares on May 21, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
May 24, 2021 Filed May 26, 2021 16:11 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 22,633 $3.76 $85,100.08
Disclosure

SEC source: 0001209191-21-035911 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,819

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
March 12, 2021 Filed Mar 15, 2021 16:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 225,000 $0.00 Strike: $20.55 $0.00
Disclosure

SEC source: 0001209191-21-020478 · doc4.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Shares · 225,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
August 20, 2020 Filed Aug 24, 2020 16:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 OtherCommon Shares 45,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-048095 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,186

F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 45,000 common shares to his spouse pursuant to the terms of a settlement agreement dated August 20, 2020 and filed with the Supreme Court of British Columbia in Vancouver, British Columbia on August 21, 2020. The settlement agreement was entered into in connection with the anticipated dissolution of the reporting person's marriage. The reporting person no longer reports as beneficially owned any securities owned by his spouse.

Read SEC document
June 01, 2020 Filed Jun 2, 2020 16:50 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 3,000 $14.43 $43,290.00
Disclosure

SEC source: 0001209191-20-033578 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,186

Read SEC document
May 29, 2020 Filed Jun 2, 2020 16:50 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 5,000 $13.99 $69,950.00
Disclosure

SEC source: 0001209191-20-033578 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,186

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
May 26, 2020 Filed May 28, 2020 17:02 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 6,172 $0.00 Strike: $3.56 $0.00
Disclosure

SEC source: 0001209191-20-032628 · doc4.xml · derivative · entry 4

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,172 shares

Expires 2020-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
May 26, 2020 Filed May 28, 2020 17:02 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,108 $14.90 $16,509.20
Disclosure

SEC source: 0001209191-20-032628 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,186

F2 · price: Represents the closing price of the Company's common shares on May 22, 2020, which was converted to a Canadian dollar amount for purposes of net settlement calculations

Read SEC document
May 26, 2020 Filed May 28, 2020 17:02 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 6,172 $3.56 $21,972.32
Disclosure

SEC source: 0001209191-20-032628 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 264,294

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
March 12, 2020 Filed Mar 13, 2020 17:00 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 280,000 $0.00 Strike: $11.58 $0.00
Disclosure

SEC source: 0001209191-20-018941 · doc4.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,000

Underlying: Common Shares · 280,000 shares

Expires 2030-03-11

F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
September 20, 2019 Filed Sep 24, 2019 18:14 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 10,395 $9.51 $98,856.45
Disclosure

SEC source: 0001209191-19-050588 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,122

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 12,345 $0.00 Strike: $3.38 $0.00
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 11

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 12,345 shares

Expires 2019-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F6 · derivative.exercise_date: The shares subject to the option fully vested on August 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 9,259 $0.00 Strike: $3.07 $0.00
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 10

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 9,259 shares

Expires 2019-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F5 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 36,008 $0.00 Strike: $3.70 $0.00
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 9

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 36,008 shares

Expires 2019-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F4 · derivative.exercise_date: The shares subject to the option fully vested on May 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 3,692 $9.44 $34,852.48
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 6

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,517

F2 · price: Represents the closing price of the Company's common shares on September 16, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 12,345 $3.38 $41,726.10
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 5

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 2,769 $9.44 $26,139.36
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 4

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,864

F2 · price: Represents the closing price of the Company's common shares on September 16, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 9,259 $3.07 $28,425.13
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 10,769 $9.44 $101,659.36
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,374

F2 · price: Represents the closing price of the Company's common shares on September 16, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
September 17, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 36,008 $3.70 $133,229.60
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 264,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 19:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 280,000 $0.00 Strike: $9.44 $0.00
Disclosure

SEC source: 0001209191-19-050148 · doc4.xml · derivative · entry 8

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,000

Underlying: Common Shares · 280,000 shares

Expires 2029-09-15

F3 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month.

Read SEC document
March 12, 2018 Filed Mar 13, 2018 17:40 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 140,000 $0.00 Strike: $4.75 $0.00
Disclosure

SEC source: 0001171843-18-001913 · formfour.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Shares · 140,000 shares

Expires 2028-03-11

F1 · derivative.exercise_date: Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
March 12, 2018 Filed Mar 14, 2018 16:52 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 10,288 $0.00 Strike: $3.77 $0.00
Disclosure

SEC source: 0001171843-18-001956 · f4_pimstone031418.xml · derivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 10,288 shares

Expires 2018-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F2 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
March 12, 2018 Filed Mar 14, 2018 16:52 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 10,288 $3.77 $38,785.76
Disclosure

SEC source: 0001171843-18-001956 · f4_pimstone031418.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
October 23, 2017 Filed Oct 24, 2017 18:46 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $3.10 $0.00
Disclosure

SEC source: 0001171843-17-006256 · formfour.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Shares · 11,000 shares

Expires 2027-10-22

F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
August 10, 2017 Filed Aug 14, 2017 18:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 PurchaseCommon Shares 6,000 $2.90 $17,400.00
Disclosure

SEC source: 0001171843-17-005069 · formfour.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,847

Read SEC document
March 13, 2017 Filed Mar 14, 2017 16:26 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 140,000 $0.00 Strike: $8.40 $0.00
Disclosure

SEC source: 0001171843-17-001507 · formfour.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Shares · 140,000 shares

Expires 2027-03-12

F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.